Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17457771 | 0.76 | ADRA1A (0.32) | — | |
| SCHEMBL16120066 | 0.69 | HTR6 (0.41) | GBA1HTR2CSLC6A4F2 | |
| SCHEMBL30664082 | 0.66 | HTR2A (0.36) | GBA1HTR2CSLC6A4APLNRGLS | |
| SCHEMBL31728221 | 0.66 | HTR2C (0.41) | HTR2CSLC6A4GLS | |
| SCHEMBL17197020 | 0.66 | KDM4E (0.47) | GBA1HTR2CSLC6A4HSD17B10PDK2 | |
| SCHEMBL27159393 | 0.66 | RORC (0.31) | HTR2CSLC6A4 | |
| SCHEMBL24192078 | 0.65 | PYCR1 (0.44) | GBA1HTR2CSLC6A4HSD17B10PDK2 | |
| SCHEMBL24192407 | 0.64 | HTR2C (0.37) | GBA1HTR2CSLC6A4AAK1HTR2A | |
| SCHEMBL7651312 | 0.64 | HTR1A (0.47) | GBA1HTR2CSLC6A4HTR2APDK2 | |
| SCHEMBL16120046 | 0.64 | HTR6 (0.36) | GBA1HTR2CSLC6A4HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | GBA1 2498/4885HTR2C 4427/4885SLC6A4 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.